Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from ...

Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...

It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...

Revolution Medicines (RVMD) announced key clinical updates from its RAS(ON) inhibitor portfolio. The data to be presented during an investor webcast today at 8:00 a.m. Eastern Time will focus on ...

A phase II study of gefitinib versus vinorelbine or gemcitabine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer based on epidermal growth factor receptor mutation ...

MONTREAL — Key genetic mutations secondary to RAS mutations that are common in differentiated thyroid cancer (DTC) strongly correlate with higher risk and more advanced cancers, as well as ...

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...

SALT LAKE CITY—Cells with a mutation in the gene called K-Ras—found in close to 30 percent of all cancers, but mostly those with worst prognosis, such as pancreatic cancer, colon cancer, and lung ...

Revolution Medicines boasts a strong cash position of $909.5M and a focus on RAS-targeted oncology but faces increased expenses and high clinical expectations. Upcoming clinical data for RMC-6236 and ...